Release Date: If one reads the earnings call transcript (2Q not 3Q) they clearly state that results will be announced 3 months after they announce enrollement completion into p3. That announcement was made September 5th or so. That would make the announcement date closer to December 5
Price: If the results are positive then looking at pharmaceuticals devoid of any significant revenue but those who have had successful Phase 3, Pre FDA approval stage for a potential block buster drug trade at a market cap of $400MM to $500MM. Current Price equates to a mkt cap of $120MM. That would point to a price of 3.3x current price on the low end. This brings us to a range of $7.2- $9. Perhaps higher if they announce a partnership.
Of course only if P3 is Positive for which I remain cautiously optimistic.
You're right about December 5 being the three-month-mark; however, the company has explicitly stated more than once (the last time in the Q3 conference call) that results would be released by the end of this month. I think we'll see them next week.